Welcome! Our research is multidisciplinary and strongly relies on synthetic organic chemistry and biophysical techniques (e.g. DSF/DSC, ITC, NMR spectroscopy), combined with chemical/structural biology and computational methods (e.g. docking, QM). Our primary focus is on the development of chemistry driven approaches to modulate proteins’ physiological activity in a wide sense, with the ultimate goal to deliver new tools to study proteins’ function in living systems. Whenever possible, we exploit the knowledge gained from these studies to attempt tackling difficult problems in human health, notably in cancer, in collaboration with teams of biologists.
PhD opportunity in synthetic chemistry and chemical biology, starting in October 2021!
We are looking to recruit a talented and motivated synthetic organic chemist to join our group and work on a new collaborative project at the chemistry/biology interface. This new project will focus on the development of novel molecular approaches to enhance the physico-chemical properties and bioactivity of small molecule chemical probes and drug candidates, with potentially profound implications in basic biological research and modern drug discovery. Strong knowledge and laboratory skills in synthetic organic chemistry will be essential. Exposure to other disciplines, for example biochemistry, cell and structural biology and biophysical techniques to study protein: small molecule interactions is a plus but not essential. If you are interested in learning more about the project, read the project description here. Note: read carefully the eligibility criteria and requirements described in the “Apply” section. For any other questions get in touch firstname.lastname@example.org!
December 2020: Joe presented a poster on his research into p53 drug discovery at the 14th RSC Biological and Medicinal Chemistry Sector Postgraduate Symposium (6-11th December 2020) where he won the Delegates Choice Prize. Well done Joe! View his poster here.
October 2020: New critical review on Current strategies for the design of PROTAC linkers published in collaboration with AstraZeneca, now online in Exploration of Targeted Anti-Tumor Therapy.
October 2020: Steve delivers a presentation on his work at the annual "Kerkut Trust Summer Meeting", which this year took place online: "Small molecule modulation of the wnt pathway: Protein-protein interaction networks and therapeutic outlook". Well done!
October 2020: We welcome Ryan and Danielle to the group for their Y4 and Y3 undergraduate research projects!
August 2020: New mini-review on p53 drug discovery published in collaboration with the Bulatov lab, now online in Frontiers in Oncology.
July 2020: We welcome to Tuncay the group for his MSc three-month project!
March 2020: Group social - Cheese and wine night
February 2020: Group social - Pancake Day
February 2020: Group social - Escape Room
December 2019: Group social - Christmas Meal joint with the Thompson group
December 2019: Secret Santa
October 2019: We welcome Megan, Oliver and Marcin who have joined the group for their Y4 and Y3 undergraduate research projects, respectively.
October 2019: We welcome Jason who has joined the group for his masters research project.
July 2019: We welcome Maeva who has joined the group as a postdoc.
May 2019: Steve presents his work at the IFLS-Chemistry for life session at the University of Southampton.
April 2019: The group attend the RSC Chemical Biology Symposium in Southampton. Joe presented a poster on PhD work on p53 drug discovery.
March 2019: Matt talks at the 2019 Chemical Biology and Bio-Organic Group (CBBG) Forum in Manchester.
April 2018: Our new paper describing chemical probes of the p53-cancer mutant Y220C is now published in the European Journal of Medicinal Chemistry.
October 2018: We welcome Dominique, Johanna and Brad who have joined the group for their Y4 and Y3 undergraduate research projects, respectively.
October 2018: We welcome Sam who has joined the group for his masters research project.
August 2018: New challenge! Our group undertakes new research towards tackling Multiple Sulfatase Deficiency, a rare and incurable disease. MSD Action Foundation and the Baud/Dierks/Radhakrishnan/Schlotawa labs join forces to advance research towards a much needed treatment for MSD.
January 2018: New paper on “Optimization of a “bump-and-hole” approach to allele-selective BET bromodomain inhibition” in collaboration with the Ciulli lab is now published in Chemical Science.
October 2017: We welcome Izzy and Amelia who have joined the group for their Y4 and Y3 undergraduate research projects, respectively.
August 2017: New paper on “Gram scale laboratory synthesis of TC AC 28, a high affinity BET bromodomain ligand” in collaboration with the Ciulli lab is now published in ACS Omega.
November 2016: Matt received the 2016 BACR/Astex Roger Griffin Prize for “the best paper on cancer drug discovery” in recognition of the “Bump and Hole” approach to target BET bromodomains, and delivered a talk at the NCRI Cancer Conference 2016, Liverpool.
The late Professor Roger Griffin
namesake of the awarded prize.
October 2016: New paper! “Toward photopharmacological antimicrobial chemotherapy using photoswitchable amidohydrolase inhibitors” in collaboration with the Fuchter lab is now published in ACS Infectious Diseases. Well done!
October 2016: We welcome Phoebe and Rory who have joined the group for their Y4 and Y3 undergraduate research projects, respectively.
September 2016: The Baud group is established in Southampton!